---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-26-000014"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:14:00.449217+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# GeneDx Q4 revenue $121M, +27% YoY; exome/genome +32%; reaffirms FY2026 guidance $540-555M

## Summary
- Q4 revenue $121M (+27% YoY); exome/genome revenue $104M (+32%, or +42% ex one-time).
- Q4 exome/genome volume 27,761 (+34.3% YoY); adjusted gross margin 71%.
- FY2025 revenue $427.5M (+41%); adjusted net income $41.8M vs $9.4M prior year.
- Reaffirmed FY2026 revenue guidance $540-555M with 33-35% exome/genome volume growth.
- Cash $172.3M; Q4 operating cash flow $5.1M; issued 147,583 shares via ATM netting $21.1M.

## SEC filing metadata
- accession: 0001818331-26-000014
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833126000014/0001818331-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833126000014/wgs-20260223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-26-000014
- JSON: https://secwatch.observer/filing/0001818331-26-000014.json
- Plain text: https://secwatch.observer/filing/0001818331-26-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.